We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
- Authors
Danila, Daniel C; Morris, Michael J; de Bono, Johann S; Ryan, Charles J; Denmeade, Samuel R; Smith, Matthew R; Taplin, Mary-Ellen; Bubley, Glenn J; Kheoh, Thian; Haqq, Christopher; Molina, Arturo; Anand, Aseem; Koscuiszka, Michael; Larson, Steve M; Schwartz, Lawrence H; Fleisher, Martin; Scher, Howard I
- Abstract
Persistence of ligand-mediated androgen receptor signaling has been documented in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and selective inhibitor of CYP17, which is required for androgen biosynthesis in the testes, adrenal glands, and prostate tissue. This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 9, p1496
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.25.9259